-
Product Insights
NewGastroenteritis – Drugs In Development, 2024
Empower your strategies with our Gastroenteritis – Drugs In Development, 2024 report and make more profitable business decisions. Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications. The Gastroenteritis drugs in development market research report provide comprehensive information on the therapeutics under development for Gastroenteritis, complete with analysis by stage...
-
Product Insights
NewGastrointestinal Radiation Toxicity – Drugs In Development, 2024
Empower your strategies with our Gastrointestinal Radiation Toxicity – Drugs In Development, 2024 report and make more profitable business decisions. Gastrointestinal radiation toxicity occurs following external beam therapy with respect to the gastrointestinal tract, the severity of toxicity is reported as grades to different symptoms or clinical manifestations ranging from minor symptomatic changes to severe life threatening complications. The Gastrointestinal Radiation Toxicity drugs in development market research report provide comprehensive information on the therapeutics under development for Gastrointestinal Radiation Toxicity, complete...
-
Product Insights
NewRespiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024
Empower your strategies with our Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Respiratory syncytial virus (RSV) infection is a respiratory disease. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache, and fever. Treatment includes proper medication and hygiene practice. The Respiratory Syncytial Virus...
-
Product Insights
NewInfluenzavirus A Infections – Drugs In Development, 2024
Empower your strategies with our Influenzavirus A Infections – Drugs In Development, 2024 report and make more profitable business decisions. Influenza A virus infections are caused by a type of influenza virus with a high capacity for genetic variation. It is more serious than the common cold and can cause major outbreaks and severe disease. It spreads through droplets from the nose or throat of an infected person, usually through coughing and sneezing. The proteins on the surface of the influenza...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Opaganib in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Opaganib in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Opaganib in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Opaganib (ABC-294640)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talimogene Laherparepvec in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talimogene Laherparepvec in Basal Cell Carcinoma...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ondansetron Hydrochloride CR in Gastroenteritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ondansetron Hydrochloride CR in Gastroenteritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ondansetron Hydrochloride CR in Gastroenteritis Drug Details: Ondansetron hydrochloride (RHB-102, Bekinda)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ondansetron Hydrochloride CR in Gastritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ondansetron Hydrochloride CR in Gastritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ondansetron Hydrochloride CR in Gastritis Drug Details: Ondansetron hydrochloride (RHB-102, Bekinda)...
-
Product Insights
NewNet Present Value Model: RedHill Biopharma Ltd’s RHB-204
Empower your strategies with our Net Present Value Model: RedHill Biopharma Ltd's RHB-204 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Redhills Solar PV Park
Redhills Solar PV Park is a solar PV project located in Utah, United States. The project is owned by MN8 Energy LLC and was developed by Scatec ASA. The project came online in 2015. Empower your strategies with our Redhills Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays....